Novartis AG
NVSEF
$157.90
$6.484.28%
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 9.88% | -1.67% | |||
| Total Other Revenue | 32.12% | -21.56% | |||
| Total Revenue | 10.55% | -2.42% | |||
| Cost of Revenue | 6.98% | -2.94% | |||
| Gross Profit | 11.77% | -2.25% | |||
| SG&A Expenses | 3.00% | -8.70% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 202.38% | -77.89% | |||
| Total Operating Expenses | 3.97% | -6.03% | |||
| Operating Income | 25.57% | 6.93% | |||
| Income Before Tax | 11.20% | 19.30% | |||
| Income Tax Expenses | 48.17% | -16.09% | |||
| Earnings from Continuing Operations | 3.20% | 31.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.42% | 31.01% | |||
| EBIT | 25.57% | 6.93% | |||
| EBITDA | 20.26% | 5.69% | |||
| EPS Basic | 3.64% | 31.28% | |||
| Normalized Basic EPS | 25.71% | 8.23% | |||
| EPS Diluted | 3.64% | 32.16% | |||
| Normalized Diluted EPS | 25.59% | 8.73% | |||
| Average Basic Shares Outstanding | -0.21% | -0.21% | |||
| Average Diluted Shares Outstanding | -0.10% | -0.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -0.55% | -- | |||